Search alternatives:
greater decrease » greater increase (Expand Search), greater increases (Expand Search), rate decreased (Expand Search)
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
greater decrease » greater increase (Expand Search), greater increases (Expand Search), rate decreased (Expand Search)
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
41
-
42
Transient neonatal olfactory deprivation causes a persistent decrease in the addition of CR+ PGCs. A
Published 2012“…The numbers of all three types of cells were significantly decreased by the 8<sup>th</sup> week of naris occlusion (<b>C</b>, red bars, <i>n</i> = 4) compared with the control group (<b>C</b>, blue bars, <i>n</i> = 5). …”
-
43
-
44
-
45
The decrease or inhibition of Hsp90 induced REST degradation.
Published 2019“…<p>(A) Effect of Hsp90α ASO on cell viability. Differentiated SH-SY5Y cells were transfected with different concentrations of Hsp90α ASO. …”
-
46
-
47
-
48
Probabilities of a decrease in coral cover by the years 2050 and 2099 relative to the year 2000.
Published 2011“…Note the 2099 “less resilient” case is the probability of a 99% or greater decrease in coral cover, other columns are for 50% or greater decrease.…”
-
49
-
50
-
51
-
52
Low concentrations of siRNA TMPRSS2-ERG III and IV impair TMPRSS2-ERG oncogene and oncoprotein levels but not cell viability.
Published 2015“…<p>VCaP cells were transfected for 72h from 2.5 nM to 50 nM with siRNA TMPRSS2-ERG III, siRNA TMPRSS2-ERG IV or siRNA Control. …”
-
53
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
Published 2025“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
-
54
-
55
-
56
-
57
-
58
-
59
-
60